Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.59 |
| ▸ | CES1 | P23141 | 2/20 | 0.59 |
| ▸ | PPARG | P37231 | 4/20 | 0.57 |
| ▸ | PPARD | Q03181 | 4/20 | 0.57 |
| ▸ | PPARA | Q07869 | 4/20 | 0.57 |
| ▸ | TERT | O14746 | 3/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | FABP4 | P15090 | 3/20 | 0.57 |
| ▸ | F7 | P08709 | 3/20 | 0.57 |
| ▸ | F3 | P13726 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28653654 | 0.85 | FAAH (0.54) | FAAHCES1PPARGPPARDPPARA | |
| SCHEMBL27347254 | 0.83 | FAAH (0.58) | FAAHCES1PPARGPPARDPPARA | |
| SCHEMBL532715 | 0.81 | FAAH (0.63) | FAAHCES1PPARGPPARDPPARA | |
| SCHEMBL532713 | 0.81 | FAAH (0.63) | FAAHCES1PPARGPPARDPPARA | |
| Hydrochloric Acid SCHEMBL6565477 | 0.79 | FAAH (0.61) | FAAHCES1PPARGPPARDPPARA | |
| SCHEMBL15956273 | 0.79 | FAAH (0.61) | FAAHCES1PPARGPPARDPPARA | |
| SCHEMBL4408909 | 0.79 | FAAH (0.61) | FAAHCES1PPARGPPARDPPARA | |
| SCHEMBL7041022 | 0.79 | FAAH (0.61) | FAAHCES1PPARGPPARDPPARA | |
| Hydrochloric Acid SCHEMBL6565479 | 0.79 | FAAH (0.61) | FAAHCES1PPARGPPARDPPARA | |
| Trimethylammonium SCHEMBL25400813 | 0.79 | FAAH (0.65) | FAAHCES1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2025-03-06 | — | — | US | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4452934-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | Providence Therapeutics Holdings Inc. (CA) | 2024-10-30 | — | — | EP | disclosed |
| US-20240200118-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240182412-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023050003-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023023055-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20220305130-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | NOVO NORDISK A/S (DK) | 2022-09-29 | — | — | US | disclosed |
| US-11351265-B2 | Process for formulating an anionic agent | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20190151461-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | DICERNA PHARMACEUTICALS, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-10137201-B2 | Process for formulating an anionic agent | DICERNA PHARMACEUTICALS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| EP-2968149-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | Dicerna Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150374842-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | NOVO NORDISK A/S (DK) | 2015-12-31 | — | — | US | disclosed |
| WO-2014153163-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | DICERNA PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | FAAH 1206/4885CES1 704/4885PPARG 1075/4885 |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | FAAH 2030/4885CES1 72/4885PPARG 795/4885 |
| US-11351265-B2 | Process for formulating an anionic agent | PHOSPHO1, POLRMT, LIPA | FAAH 1051/4885CES1 1128/4885PPARG 1751/4885 |
| US-20190151461-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | PHOSPHO1, POLRMT, LIPA | FAAH 1051/4885CES1 1128/4885PPARG 1751/4885 |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | SGMS1, SGMS2, ABCB4 | FAAH 3070/4885CES1 1906/4885PPARG 2222/4885 |
| US-10137201-B2 | Process for formulating an anionic agent | PHOSPHO1, POLRMT, LIPA | FAAH 1051/4885CES1 1128/4885PPARG 1751/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | FAAH 2196/4885CES1 2327/4885PPARG 2837/4885 |
| US-20220305130-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | PHOSPHO1, POLRMT, LIPA | FAAH 1051/4885CES1 1128/4885PPARG 1751/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | FAAH 1206/4885CES1 704/4885PPARG 1075/4885 |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | FAAH 2169/4885CES1 756/4885PPARG 2631/4885 |
| US-20150374842-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | PHOSPHO1, POLRMT, LIPA | FAAH 1051/4885CES1 1128/4885PPARG 1751/4885 |
| US-20240182412-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | FAAH 2169/4885CES1 756/4885PPARG 2631/4885 |
| US-20240200118-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | NSUN3, PHAX, RNGTT | FAAH 4068/4885CES1 1645/4885PPARG 3770/4885 |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | FAAH 2169/4885CES1 756/4885PPARG 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.